Literature DB >> 18365217

[Myalgia in Neuro-Behçet's disease. Medication side effects or expression of underlying disease].

M Krämer1, M W Baumgärtel, E Neuen-Jacob, P Berlit.   

Abstract

In this report we present the 9-year course of disease in a woman of Turkish origin suffering from Behçet's disease with parenchymal CNS involvement combined with myalgia. Differential diagnoses, such as drug-induced neuromyopathy were excluded on the basis of electromyographic and bioptic tests. We were able to arrest progression of symptoms of both the myopathy and the Neuro-Behçet's disease by means of increased combined immunosuppressive therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18365217     DOI： 10.1007/s00393-008-0285-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  18 in total

1.  HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha.

Authors:  I Kötter; C Aepinus; F Graepler; V Gärtner; A K Eckstein; N Stübiger; B Kaskas; M Zierhut; B Bültmann; R Kandolf; L Kanz
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 2.  Necrotising myositis in Behçet's disease: characteristic features on magnetic resonance imaging and a review of the literature.

Authors:  H Sarui; T Maruyama; I Ito; N Yamakita; N Takeda; M Nose; K Yasuda
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

3.  Peripheral neuropathy in Behçet's disease.

Authors:  Ahu Birol; Sedat Ulkatan; Mukadder Koçak; Emel Erkek
Journal:  J Dermatol       Date:  2004-06       Impact factor: 4.005

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

5.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 6.  The risk of neoplasms in patients treated with cyclosporine A.

Authors:  I T Cockburn; P Krupp
Journal:  J Autoimmun       Date:  1989-10       Impact factor: 7.094

Review 7.  Muscular involvement in Behçet's disease: case report and review of the literature.

Authors:  F Worthmann; J Bruns; T Türker; G Gosztonyi
Journal:  Neuromuscul Disord       Date:  1996-08       Impact factor: 4.296

8.  Localized myositis in Behçet's disease.

Authors:  H Yazici; N Tüzüner; Y Tüzün; S Yurdakul
Journal:  Arthritis Rheum       Date:  1981-04

9.  [Behçet's disease with atypical double neurological involvement].

Authors:  E Durán; J R Chacón
Journal:  Rev Neurol       Date:  2001 Aug 16-31       Impact factor: 0.870

10.  [A case of Behçet's disease associated with neuromyopathy induced by combination therapy with colchicine and cyclosporin].

Authors:  Yuko Fujii; Yoshihiro Arimura; Naoko Takahashi; Takeshi Toki; Tomofumi Marumo; Ken Yoshihara; Kimimasa Nakabayashi; Akira Yamada
Journal:  Ryumachi       Date:  2003-02
View more
  3 in total

1.  Primary central nervous system vasculitis: clinical experiences with 21 new European cases.

Authors:  Markus Kraemer; Peter Berlit
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

2.  [Epidemiology and clinical aspects of Adamantiades-Behçet disease in Gemany. Current data].

Authors:  A Altenburg; A Mahr; C Maldini; C E Kneifel; L Krause; I Kötter; T Stache; N G Bonitsis; C C Zouboulis
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

3.  Musculoskeletal Findings in Behcet's Disease.

Authors:  Ali Bicer
Journal:  Patholog Res Int       Date:  2011-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.